Stay updated on Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-03-03T22:15:51.000Z thumbnail image
  3. Check
    26 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:29:16.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T05:30:10.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.0 to v2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T03:17:16.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.
    Difference
    0.2%
    Check dated 2025-01-12T23:19:42.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    The latest update on the phase II study reveals that participants will be randomized into three arms to receive different combinations of VRP-HER2 immunizations and pembrolizumab, with results now posted detailing the number of participants with severe adverse events and stable disease based on RECIST criteria.
    Difference
    15%
    Check dated 2024-12-15T00:04:25.000Z thumbnail image

Stay in the know with updates to Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.